D. Scott Ernst

5.8k total citations · 1 hit paper
77 papers, 4.3k citations indexed

About

D. Scott Ernst is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, D. Scott Ernst has authored 77 papers receiving a total of 4.3k indexed citations (citations by other indexed papers that have themselves been cited), including 51 papers in Pulmonary and Respiratory Medicine, 36 papers in Oncology and 25 papers in Molecular Biology. Recurrent topics in D. Scott Ernst's work include Renal cell carcinoma treatment (31 papers), Cancer Genomics and Diagnostics (19 papers) and Renal and related cancers (15 papers). D. Scott Ernst is often cited by papers focused on Renal cell carcinoma treatment (31 papers), Cancer Genomics and Diagnostics (19 papers) and Renal and related cancers (15 papers). D. Scott Ernst collaborates with scholars based in Canada, United States and Japan. D. Scott Ernst's co-authors include Malcolm J. Moore, David Osoba, Peter Venner, I. F. Tannock, A. J. Neville, Martin R. Stockler, George Armitage, C Coppin, Jonathan J. Wilson and Ian F. Tannock and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and The Lancet Oncology.

In The Last Decade

D. Scott Ernst

73 papers receiving 4.2k citations

Hit Papers

Chemotherapy with mitoxan... 1996 2026 2006 2016 1996 400 800 1.2k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points.
    1996 1.2k citations I. F. Tannock, David Osoba et al. Journal of Clinical Oncology profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author Last Decade Papers Cites
D. Scott Ernst 2.8k 1.8k 1.2k 925 767 77 4.3k
Aristotelis Bamias 2.2k 0.8× 3.1k 1.7× 1.7k 1.3× 1.9k 2.1× 829 1.1× 276 6.9k
Bernhard J. Eigl 3.2k 1.1× 1.5k 0.9× 1.7k 1.4× 820 0.9× 1.6k 2.0× 135 4.6k
Marie‐Cécile Le Deley 1.9k 0.7× 1.3k 0.7× 1.0k 0.8× 682 0.7× 501 0.7× 177 5.0k
Lance C. Pagliaro 2.4k 0.8× 2.1k 1.2× 1.6k 1.3× 2.1k 2.2× 1.0k 1.3× 199 5.9k
Giuseppe Procopio 3.1k 1.1× 2.7k 1.5× 1.5k 1.2× 615 0.7× 1.2k 1.6× 360 5.2k
Umberto Basso 1.7k 0.6× 2.1k 1.2× 1.0k 0.8× 775 0.8× 736 1.0× 236 4.7k
Jonathan Polikoff 2.0k 0.7× 2.5k 1.4× 694 0.6× 781 0.8× 909 1.2× 70 4.7k
Martin E. Blackstein 3.9k 1.4× 2.0k 1.1× 1.0k 0.8× 1.6k 1.7× 561 0.7× 101 6.3k
Lina Asmar 2.7k 0.9× 3.9k 2.2× 926 0.8× 605 0.7× 2.1k 2.8× 169 6.4k
Laura S. Wood 3.1k 1.1× 2.3k 1.3× 2.2k 1.8× 525 0.6× 1.4k 1.9× 99 4.9k

Countries citing papers authored by D. Scott Ernst

Since Specialization
Citations

This map shows the geographic impact of D. Scott Ernst's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by D. Scott Ernst with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites D. Scott Ernst more than expected).

Fields of papers citing papers by D. Scott Ernst

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by D. Scott Ernst. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by D. Scott Ernst. The network helps show where D. Scott Ernst may publish in the future.

Co-authorship network of co-authors of D. Scott Ernst

This figure shows the co-authorship network connecting the top 25 collaborators of D. Scott Ernst. A scholar is included among the top collaborators of D. Scott Ernst based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with D. Scott Ernst. D. Scott Ernst is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Bhindi, Bimal, Jeffrey Graham, J. Connor Wells, et al.. (2020). Deferred Cytoreductive Nephrectomy in Patients with Newly Diagnosed Metastatic Renal Cell Carcinoma. European Urology. 78(4). 615–623. 42 indexed citations
3.
Claveau, Joël, Jean Archambault, D. Scott Ernst, et al.. (2020). Multidisciplinary Management of Locally Advanced and Metastatic Cutaneous Squamous Cell Carcinoma. Current Oncology. 27(4). 399–407. 37 indexed citations
4.
Stukalin, Igor, J. Connor Wells, Jeffrey Graham, et al.. (2019). Real-World Outcomes of Nivolumab and Cabozantinib in Metastatic Renal Cell Carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium. Current Oncology. 26(2). 175–179. 22 indexed citations
5.
Bjarnason, Georg A., Jennifer J. Knox, Christian Kollmannsberger, et al.. (2019). The efficacy and safety of sunitinib given on an individualised schedule as first-line therapy for metastatic renal cell carcinoma: A phase 2 clinical trial. European Journal of Cancer. 108. 69–77. 24 indexed citations
6.
Graham, Jeffrey, J. Connor Wells, Frede Donskov, et al.. (2019). Cytoreductive Nephrectomy in Metastatic Papillary Renal Cell Carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium. European Urology Oncology. 2(6). 643–648. 31 indexed citations
7.
Thompson, John A., Robert J. Motzer, Ana M. Molina, et al.. (2018). Phase I Trials of Anti-ENPP3 Antibody–Drug Conjugates in Advanced Refractory Renal Cell Carcinomas. Clinical Cancer Research. 24(18). 4399–4406. 48 indexed citations
8.
9.
Basset‐Séguin, Nicole, Axel Hauschild, Jean‐Jacques Grob, et al.. (2015). Vismodegib in patients with advanced basal cell carcinoma (STEVIE): a pre-planned interim analysis of an international, open-label trial. The Lancet Oncology. 16(6). 729–736. 170 indexed citations
10.
11.
Gupta, Shruti, et al.. (2014). ECF chemotherapy for liver metastases due to castration-resistant prostate cancer. Canadian Urological Association Journal. 8(9-10). 353–353. 2 indexed citations
12.
Heng, Daniel Y.C., J. Connor Wells, Brian I. Rini, et al.. (2014). Cytoreductive Nephrectomy in Patients with Synchronous Metastases from Renal Cell Carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium. European Urology. 66(4). 704–710. 311 indexed citations
13.
Ernst, D. Scott, et al.. (2012). Consolidative high-dose chemotherapy after conventional-dose chemotherapy as first salvage treatment for male patients with metastatic germ cell tumours. Canadian Urological Association Journal. 6(2). 111–116. 3 indexed citations
14.
15.
Winquist, Eric, Malcolm J. Moore, Kim N., et al.. (2005). A multinomial Phase II study of lonafarnib (SCH 66336) in patients with refractory urothelial cancer☆. Urologic Oncology Seminars and Original Investigations. 23(3). 143–149. 44 indexed citations
16.
Saliken, John C., D. Scott Ernst, Bryce Weber, et al.. (2005). Role of transrectal ultrasound guided salvage cryosurgery for recurrent prostate carcinoma after radiotherapy. Prostate Cancer and Prostatic Diseases. 8(3). 235–242. 46 indexed citations
17.
Moore, Malcolm J., Ian F. Tannock, D. Scott Ernst, S. Huan, & Nevin Murray. (1997). Gemcitabine: a promising new agent in the treatment of advanced urothelial cancer.. Journal of Clinical Oncology. 15(12). 3441–3445. 222 indexed citations
18.
Ernst, D. Scott, Penny Brasher, Neil A. Hagen, et al.. (1997). A randomized, controlled trial of intravenous clodronate in patients with metastatic bone disease and pain. Journal of Pain and Symptom Management. 13(6). 319–326. 75 indexed citations
19.
Tannock, I. F., David Osoba, Martin R. Stockler, et al.. (1996). Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points.. Journal of Clinical Oncology. 14(6). 1756–1764. 1202 indexed citations breakdown →
20.
Paterson, Alexander, D. Scott Ernst, T.J. Powles, et al.. (1991). Treatment of skeletal disease in breast cancer with clodronate. Bone. 12. S25–S30. 29 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Aristotelis Bamias Breakdown of academic impact, for papers by Bernhard J. Eigl Breakdown of academic impact, for papers by Marie‐Cécile Le Deley Breakdown of academic impact, for papers by Lance C. Pagliaro Breakdown of academic impact, for papers by Giuseppe Procopio Breakdown of academic impact, for papers by Umberto Basso Breakdown of academic impact, for papers by Jonathan Polikoff Breakdown of academic impact, for papers by Martin E. Blackstein Breakdown of academic impact, for papers by Lina Asmar Breakdown of academic impact, for papers by Laura S. Wood
Rankless by CCL
2026